Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Medical Oncology Department, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, 08036 Barcelona, Spain.
Gastrointestinal and Pancreatic Oncology Group, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, 08036 Barcelona, Spain.
Int J Mol Sci. 2021 May 9;22(9):5019. doi: 10.3390/ijms22095019.
Insulin-like growth factor 1 receptor (IGF1R) is a receptor tyrosine kinase that regulates cell growth and proliferation. Upregulation of the IGF1R pathway constitutes a common paradigm shared with other receptor tyrosine kinases such as EGFR, HER2, and MET in different cancer types, including colon cancer. The main IGF1R signaling pathways are PI3K-AKT and MAPK-MEK. However, different processes, such as post-translational modification (SUMOylation), epithelial-to-mesenchymal transition (EMT), and microenvironment complexity, can also contribute to intrinsic and acquired resistance. Here, we discuss new strategies for adequate drug development in metastatic colorectal cancer patients.
胰岛素样生长因子 1 受体（IGF1R）是一种受体酪氨酸激酶，可调节细胞生长和增殖。IGF1R 通路的上调与其他受体酪氨酸激酶（如 EGFR、HER2 和 MET）在不同癌症类型（包括结肠癌）中共同构成了一个常见的范例。IGF1R 的主要信号通路是 PI3K-AKT 和 MAPK-MEK。然而，不同的过程，如翻译后修饰（SUMOylation）、上皮-间充质转化（EMT）和微环境的复杂性，也可以导致内在和获得性耐药。在这里，我们讨论了转移性结直肠癌患者药物开发的新策略。
